Table 3

Cox proportional hazard regression of risk of CRC and cancer stratified by NAT2 genotype

Univariate resultsMultivariate results (adjusted by NAT2*5, NAT2*6, and NAT2*7)
HR95% CI-La95% CI-UbPHR95% CI-L95% CI-UP
CRC
NAT2*5 (wtc/wt)11
NAT2*5 (wt/md)1.700.9692.9850.06402.381.3324.2510.0034
NAT2*5 (m/m)1.200.3883.6910.76001.60.4955.1810.4300
NAT2*6 (wt/wt)11
NAT2*6 (wt/m)0.620.3511.0860.09400.750.4151.3500.3300
NAT2*6 (m/m)0.940.3682.3700.89001.820.5865.6740.3000
NAT2*7 (wt/wt)11
NAT2*7 (wt/m)2.100.9894.4750.05302.961.2806.8540.0120
NAT2*7 (m/m)
Cancer
NAT2*5 (wt/wt)11
NAT2*5 (wt/m)1.220.6862.1630.50001.340.7302.4600.3500
NAT2*5 (m/m)1.10.4352.7760.84001.130.4093.1060.8200
NAT2*6 (wt/wt)11
NAT2*6 (wt/m)0.590.3401.0310.06400.630.3271.2160.1700
NAT2*6 (m/m)0.70.2661.8230.46000.940.3002.9480.9200
NAT2*7 (wt/wt)11
NAT2*7 (wt/m)2.821.7614.5460.000013.371.9185.9090.00004
NAT2*7 (m/m)
  • a CI-L, lower boundary of 95% confidence interval.

  • b CI-U, upper boundary of 95% confidence interval.

  • c WT, wild type at this NAT2 locus.

  • d M, mutant at this NAT2 locus.